{"id":4079,"date":"2026-08-18T14:56:38","date_gmt":"2026-08-18T12:56:38","guid":{"rendered":"https:\/\/mumak.me\/?p=4079"},"modified":"2026-08-18T16:35:43","modified_gmt":"2026-08-18T14:35:43","slug":"valuation-analysis-johnson-johnson","status":"publish","type":"post","link":"https:\/\/mumak.me\/en\/research-insights\/valuation-analysis\/valuation-analysis-johnson-johnson\/","title":{"rendered":"Valuation Analysis: Johnson &#038; Johnson"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-post\" data-elementor-id=\"4079\" class=\"elementor elementor-4079 elementor-4078\" data-elementor-post-type=\"post\">\n\t\t\t\t<div class=\"elementor-element elementor-element-ab0bcff e-flex e-con-boxed e-con e-parent\" data-id=\"ab0bcff\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-a554d44 elementor-widget elementor-widget-mumak_score_card\" data-id=\"a554d44\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"mumak_score_card.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div class=\"mumak-score-card is-detail\" data-view=\"overall\" style=\"--mumak-mammoth-mask: url(&quot;https:\/\/mumak.me\/wp-content\/uploads\/2026\/03\/Mammut-Clean-2.svg&quot;);\">\n\t\t\t\t\t\t\t\t\t<div class=\"mumak-score-card__detail mumak-score-card__detail--overall\">\n\t\t\t<div class=\"mumak-score-card__detail-compass-wrap\">\n\t\t\t\t<img decoding=\"async\" class=\"mumak-score-card__detail-compass\" src=\"https:\/\/mumak.me\/wp-content\/uploads\/2026\/03\/Compass-Circle.svg\" alt=\"\" aria-hidden=\"true\">\n\t\t\t<\/div>\n\t\t\t<div class=\"mumak-score-card__detail-content\">\n\t\t\t\t<h4 class=\"mumak-score-card__company\">Johnson &amp; Johnson<\/h4>\n\t\t\t\t<div class=\"mumak-score-card__detail-mammoths\" aria-hidden=\"true\">\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"mumak-score-card__detail-mammoth is-active-positive\"><\/span>\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"mumak-score-card__detail-mammoth is-active-positive\"><\/span>\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"mumak-score-card__detail-mammoth is-active-positive\"><\/span>\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"mumak-score-card__detail-mammoth is-active-positive\"><\/span>\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"mumak-score-card__detail-mammoth is-active-positive\"><\/span>\n\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"mumak-score-card__detail-result\">\n\t\t\t\t\tAnalysis result: 5 out of 5 MUMAKS\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-7cecee3 elementor-widget elementor-widget-text-editor\" data-id=\"7cecee3\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p class=\"PDq2pG_selectionAnchorContainer\" data-start=\"0\" data-end=\"117\">Since our last analysis, Johnson &amp; Johnson has continued its positive operational and strategic development.<\/p><p data-start=\"119\" data-end=\"568\">The company published <strong data-start=\"151\" data-end=\"245\">strong results for the second quarter of 2026 and raised its full-year guidance<\/strong>. At the same time, Johnson &amp; Johnson achieved further progress in its pharmaceutical product pipeline and announced a <strong data-start=\"370\" data-end=\"479\">proposed settlement for the remaining lawsuits related to ovarian cancer and talc products<\/strong>. This could significantly reduce a long-standing legal uncertainty.  <\/p><p data-start=\"570\" data-end=\"756\">The technical picture has also improved. The share price has risen above its previous resistance level, while RSI and MACD continue to indicate positive momentum. <\/p><p data-start=\"758\" data-end=\"857\" data-is-last-node=\"\" data-is-only-node=\"\">Overall, recent developments confirm our positive assessment of Johnson &amp; Johnson.<\/p><h2>Rating<\/h2><p><span data-contrast=\"none\">This analysis evaluates Johnson &amp; Johnson according to the UMBRELLA strategy using the MUMAK method. <\/span><\/p><p><span data-contrast=\"none\">The valuation is conducted across five decision-making phases: <strong>Geopolitics<\/strong>, <strong>Industry<\/strong>, <strong>Fundamentals<\/strong>, <strong>Market Sentiment<\/strong>, and <strong>Technical Analysis.<\/strong><\/span><\/p><p><span data-contrast=\"none\">The goal is not to predict the future precisely. The goal is orientation. We contextualize facts, demonstrate causal relationships, and structure a comprehensible decision logic.  <\/span><span data-ccp-props=\"{\"> <\/span><\/p><p><b><span data-contrast=\"none\">We explain \u2013 you decide.<\/span><\/b><span data-ccp-props=\"{\"> <\/span><\/p><h3>Geopolitics<\/h3><h4><strong>Classification <\/strong><\/h4><p class=\"PDq2pG_selectionAnchorContainer\" data-start=\"0\" data-end=\"119\">The geopolitical and demographic environment remains supportive for the global healthcare industry as a whole.<\/p><p data-start=\"121\" data-end=\"372\">Aging populations, rising healthcare spending, and growing demand for innovative therapies create structural growth opportunities, particularly in oncology, immunology, cardiovascular disease, and medical technology.<\/p><p data-start=\"374\" data-end=\"608\">Johnson &amp; Johnson benefits from its global presence and broadly diversified product portfolio. In addition, demand in the healthcare sector is typically far less cyclical than in many other industries. <\/p><p data-start=\"610\" data-end=\"858\">However, governments in the United States and Europe are increasingly focused on containing healthcare costs. Drug pricing, reimbursement policy, and regulatory intervention therefore remain important structural risks. <\/p><h5 data-start=\"860\" data-end=\"871\"><strong data-start=\"860\" data-end=\"871\">Opportunities<\/strong><\/h5><ul data-start=\"873\" data-end=\"1363\"><li data-section-id=\"izk2on\" data-start=\"873\" data-end=\"975\">Aging populations support structurally rising demand for healthcare services.<\/li><li data-section-id=\"1diph7j\" data-start=\"976\" data-end=\"1071\">Oncology, immunology, and neuroscience remain important long-term growth markets.<\/li><li data-section-id=\"me6q5t\" data-start=\"1072\" data-end=\"1180\">Healthcare spending proves comparatively robust even during economic downturns.<\/li><li data-section-id=\"1ss67zw\" data-start=\"1181\" data-end=\"1274\">Johnson &amp; Johnson&#8217;s global presence reduces dependence on individual markets.<\/li><li data-section-id=\"1rutads\" data-start=\"1275\" data-end=\"1363\">Innovations in medical technology create additional structural growth opportunities.<\/li><\/ul><h5 data-start=\"1365\" data-end=\"1376\"><strong data-start=\"1365\" data-end=\"1376\">Risks<\/strong><\/h5><ul data-start=\"1378\" data-end=\"1760\"><li data-section-id=\"1sok4n5\" data-start=\"1378\" data-end=\"1478\">Increasing political pressure on drug pricing, particularly in the United States.<\/li><li data-section-id=\"imbb47\" data-start=\"1479\" data-end=\"1587\">Reimbursement system reforms could limit pricing power for innovative drugs.<\/li><li data-section-id=\"1eaio2j\" data-start=\"1588\" data-end=\"1651\">Regulatory requirements are becoming increasingly complex.<\/li><li data-section-id=\"1kr6z9p\" data-start=\"1652\" data-end=\"1760\">Global supply chains in the pharmaceutical and medical technology industries remain exposed to geopolitical disruptions.<\/li><\/ul><p data-start=\"1762\" data-end=\"1787\"><strong>Key takeaway: <\/strong>Demographic trends and structurally rising demand for healthcare services create a favorable long-term environment for Johnson &amp; Johnson.<\/p><p><b><span data-contrast=\"none\">MUMAK.me Rating Phase 1: Positive = 1 MUMAK<\/span><\/b><span data-ccp-props=\"{}\"> <\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-cd781cf elementor-widget elementor-widget-mumak_score_card\" data-id=\"cd781cf\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"mumak_score_card.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div class=\"mumak-score-card is-detail\" data-view=\"geopolitik\" style=\"--mumak-mammoth-mask: url(&quot;https:\/\/mumak.me\/wp-content\/uploads\/2026\/03\/Mammut-Clean-2.svg&quot;);\">\n\t\t\t\t\t\t\t\t\t<div class=\"mumak-score-card__detail\">\n\t\t\t<div class=\"mumak-score-card__detail-compass-wrap\">\n\t\t\t\t<img decoding=\"async\" class=\"mumak-score-card__detail-compass\" src=\"https:\/\/mumak.me\/wp-content\/uploads\/2026\/03\/Compass-Circle.svg\" alt=\"\" aria-hidden=\"true\">\n\t\t\t<\/div>\n\t\t\t<div class=\"mumak-score-card__detail-content\">\n\t\t\t\t<h4 class=\"mumak-score-card__company\">Johnson &amp; Johnson<\/h4>\n\t\t\t\t<div class=\"mumak-score-card__detail-mammoths\" aria-hidden=\"true\">\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"mumak-score-card__detail-mammoth is-active-positive\"><\/span>\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"mumak-score-card__detail-mammoth is-default\"><\/span>\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"mumak-score-card__detail-mammoth is-default\"><\/span>\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"mumak-score-card__detail-mammoth is-default\"><\/span>\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"mumak-score-card__detail-mammoth is-default\"><\/span>\n\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"mumak-score-card__detail-result\">\n\t\t\t\t\tRating Geopolitics: positiv\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-7538b74 elementor-widget elementor-widget-text-editor\" data-id=\"7538b74\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<h3>Industry<\/h3><h4><b><span data-contrast=\"none\">Assessment<\/span><\/b><span data-ccp-props=\"{\"> <\/span><\/h4><p class=\"PDq2pG_selectionAnchorContainer\" data-start=\"0\" data-end=\"97\">The healthcare sector remains one of the most attractive industries globally with structural growth.<\/p><p data-start=\"99\" data-end=\"268\">Johnson &amp; Johnson holds a particularly strong position, as the company combines two complementary business segments: <strong data-start=\"232\" data-end=\"267\">Innovative Medicine and MedTech<\/strong>.<\/p><p data-start=\"270\" data-end=\"516\">The pharmaceutical business offers access to high-growth areas such as oncology, immunology, and neuroscience, while MedTech provides additional diversification through surgery, cardiovascular technologies, orthopedics, and ophthalmology.<\/p><p data-start=\"518\" data-end=\"676\" data-is-last-node=\"\" data-is-only-node=\"\">This diversification reduces dependence on individual therapeutic areas and distinguishes Johnson &amp; Johnson from many competitors in the pharmaceutical industry.<\/p><h5><span data-contrast=\"none\">Johnson &amp; Johnson in Valuation Comparison<\/span><span data-ccp-props=\"{\"> <\/span><\/h5>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-579aa8a elementor-widget elementor-widget-Table\" data-id=\"579aa8a\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"Table.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<table class=\"tafe-table \">\n\t\t\t<thead  class=\"tafe-table-header\">\n\t\t\t\t<tr>\n\t\t\t\t\t<th class=\"elementor-inline-editing elementor-repeater-item-3f3f2e0\"   >Key Figure<\/th><th class=\"elementor-inline-editing elementor-repeater-item-f44885d\"   >Johnson &amp; Johnson 2026e<\/th><th class=\"elementor-inline-editing elementor-repeater-item-23de24f\"   >Industry average*  <\/th><th class=\"elementor-inline-editing elementor-repeater-item-160e477\"   >Rating<\/th>\t\t\t\t<\/tr>\n\t\t\t<\/thead>\n\t\t\t\t\t\t<tbody class=\"tafe-table-body\">\n\t\t\t\t<tr>\n\t\t\t\t\t<\/tr><tr><td data-label=\"Key Figure\"   class=\"elementor-repeater-item-e050aa7 td-content-type-default\" ><b>P\/E 2026e <\/b><\/td><td data-label=\"Johnson &amp; Johnson 2026e\"   class=\"elementor-repeater-item-da32a54 td-content-type-default\" >29.2x <\/td><td data-label=\"Industry average*\"   class=\"elementor-repeater-item-f04d525 td-content-type-default\" >approx. 21\u201324x  <\/td><td data-label=\"Rating\"   class=\"elementor-repeater-item-88aee7f td-content-type-default\" >Weaker \/ Highly valued<\/td><\/tr><tr><td data-label=\"Key Figure\"   class=\"elementor-repeater-item-66a0f10 td-content-type-default\" ><b>EBIT margin <\/b><\/td><td data-label=\"Johnson &amp; Johnson 2026e\"   class=\"elementor-repeater-item-8d40194 td-content-type-default\" >32 % \n<\/td><td data-label=\"Industry average*\"   class=\"elementor-repeater-item-7647d0a td-content-type-default\" >approx. 22\u201328%\n<\/td><td data-label=\"Rating\"   class=\"elementor-repeater-item-5d8d262 td-content-type-default\" >Stronger\n<\/td><\/tr><tr><td data-label=\"Key Figure\"   class=\"elementor-repeater-item-7c6426a td-content-type-default\" ><b>Net margin  <\/b><\/td><td data-label=\"Johnson &amp; Johnson 2026e\"   class=\"elementor-repeater-item-60bcf94 td-content-type-default\" >approx. 29%\n<\/td><td data-label=\"Industry average*\"   class=\"elementor-repeater-item-1e54240 td-content-type-default\" >approx. 17\u201323%\n<\/td><td data-label=\"Rating\"   class=\"elementor-repeater-item-6ac8267 td-content-type-default\" >Stronger\n<\/td><\/tr><tr><td data-label=\"Key Figure\"   class=\"elementor-repeater-item-d27b099 td-content-type-default\" ><b>Revenue Growth <\/b><\/td><td data-label=\"Johnson &amp; Johnson 2026e\"   class=\"elementor-repeater-item-08a1df6 td-content-type-default\" >approx. 7%\n<\/td><td data-label=\"Industry average*\"   class=\"elementor-repeater-item-3dfb4de td-content-type-default\" >approx. 4\u20137%\n<\/td><td data-label=\"Rating\"   class=\"elementor-repeater-item-13b2ed6 td-content-type-default\" >In line  \n<\/td><\/tr><tr><td data-label=\"Key Figure\"   class=\"elementor-repeater-item-e014835 td-content-type-default\" ><b>Dividend Yield <\/b><\/td><td data-label=\"Johnson &amp; Johnson 2026e\"   class=\"elementor-repeater-item-96a1917 td-content-type-default\" >approx. 2% \n<\/td><td data-label=\"Industry average*\"   class=\"elementor-repeater-item-4234277 td-content-type-default\" >approx. 2.0\u20132.5%  \n<\/td><td data-label=\"Rating\"   class=\"elementor-repeater-item-eb661a9 td-content-type-default\" >In line\n<\/td>\t\t\t\t<\/tr>\n\t\t\t<\/tbody>\n\t\t<\/table>\n\t\t\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-037c573 elementor-widget elementor-widget-text-editor\" data-id=\"037c573\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p><em><span class=\"TextRun SCXW174218123 BCX4\" lang=\"DE-AT\" data-contrast=\"none\"><span class=\"NormalTextRun SCXW174218123 BCX4\">* <\/span><\/span><span class=\"TextRun SCXW174218123 BCX4\" lang=\"DE-AT\" data-contrast=\"none\"><span class=\"NormalTextRun SCXW174218123 BCX4\">Peer group:<\/span><\/span><span class=\"TextRun SCXW174218123 BCX4\" lang=\"DE-AT\" data-contrast=\"none\"><span class=\"NormalTextRun SCXW174218123 BCX4\"> Roche, Merck &amp; Co., Novartis, AstraZeneca, Abbott Laboratories, and AbbVie. <\/span><\/span><span class=\"TextRun SCXW174218123 BCX4\" lang=\"DE-AT\" data-contrast=\"none\"><span class=\"NormalTextRun SpellingErrorV2Themed SCXW174218123 BCX4\">Source:<\/span><\/span><span class=\"TextRun SCXW174218123 BCX4\" lang=\"DE-AT\" data-contrast=\"none\"><span class=\"NormalTextRun SpellingErrorV2Themed SCXW174218123 BCX4\">MarketScreener<\/span><span class=\"NormalTextRun SCXW174218123 BCX4\"> consensus estimates and market data, August 2026.<\/span><\/span><span class=\"EOP Selected SCXW174218123 BCX4\" data-ccp-props=\"{\"> <\/span><\/em><\/p><h5><strong data-start=\"0\" data-end=\"11\">Opportunities<\/strong><\/h5><ul data-start=\"13\" data-end=\"510\"><li data-section-id=\"1v7hcnr\" data-start=\"13\" data-end=\"91\">Innovative Medicine offers access to structurally growing therapeutic markets.<\/li><li data-section-id=\"17a375e\" data-start=\"92\" data-end=\"190\">MedTech provides additional diversification and reduces dependence on the pharmaceutical business.<\/li><li data-section-id=\"19jcrev\" data-start=\"191\" data-end=\"287\">Oncology remains one of the strongest long-term growth areas in the healthcare sector.<\/li><li data-section-id=\"dfvjpk\" data-start=\"288\" data-end=\"407\">The company&#8217;s size enables substantial investments in research, clinical development, and acquisitions.<\/li><li data-section-id=\"ynouhw\" data-start=\"408\" data-end=\"510\">A broadly diversified portfolio reduces dependence on individual blockbuster products.<\/li><\/ul><h5 data-start=\"512\" data-end=\"523\"><strong data-start=\"512\" data-end=\"523\">Risks<\/strong><\/h5><ul data-start=\"525\" data-end=\"937\"><li data-section-id=\"hr2upt\" data-start=\"525\" data-end=\"645\">Johnson &amp; Johnson is trading at a valuation premium relative to parts of the pharmaceutical peer group.<\/li><li data-section-id=\"16td2sj\" data-start=\"646\" data-end=\"730\">Patent expirations can significantly impact the development of individual products.<\/li><li data-section-id=\"c7nf9v\" data-start=\"731\" data-end=\"833\">Competition for innovative therapies in oncology and immunology remains intense.<\/li><li data-section-id=\"vaylyw\" data-start=\"834\" data-end=\"937\">Rising healthcare costs increase political pressure as well as pressure on reimbursement systems.<\/li><\/ul><p><strong>Key takeaway:<\/strong> The combination of Innovative Medicine and MedTech makes Johnson &amp; Johnson an exceptionally diversified healthcare platform. The higher valuation reflects this quality, but at the same time reduces the <strong data-start=\"1188\" data-end=\"1223\">margin of safety for investors<\/strong>. <\/p><p><b><span data-contrast=\"none\">MUMAK.me Evaluation Phase 2: positive = 1 MUMAK<\/span><\/b><span data-ccp-props=\"{}\"> <\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-a0197e6 elementor-widget elementor-widget-mumak_score_card\" data-id=\"a0197e6\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"mumak_score_card.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div class=\"mumak-score-card is-detail\" data-view=\"branche\" style=\"--mumak-mammoth-mask: url(&quot;https:\/\/mumak.me\/wp-content\/uploads\/2026\/03\/Mammut-Clean-2.svg&quot;);\">\n\t\t\t\t\t\t\t\t\t<div class=\"mumak-score-card__detail\">\n\t\t\t<div class=\"mumak-score-card__detail-compass-wrap\">\n\t\t\t\t<img decoding=\"async\" class=\"mumak-score-card__detail-compass\" src=\"https:\/\/mumak.me\/wp-content\/uploads\/2026\/03\/Compass-Circle.svg\" alt=\"\" aria-hidden=\"true\">\n\t\t\t<\/div>\n\t\t\t<div class=\"mumak-score-card__detail-content\">\n\t\t\t\t<h4 class=\"mumak-score-card__company\">Johnson &amp; Johnson<\/h4>\n\t\t\t\t<div class=\"mumak-score-card__detail-mammoths\" aria-hidden=\"true\">\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"mumak-score-card__detail-mammoth is-inactive-positive\"><\/span>\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"mumak-score-card__detail-mammoth is-active-positive\"><\/span>\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"mumak-score-card__detail-mammoth is-default\"><\/span>\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"mumak-score-card__detail-mammoth is-default\"><\/span>\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"mumak-score-card__detail-mammoth is-default\"><\/span>\n\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"mumak-score-card__detail-result\">\n\t\t\t\t\tRating Industry: positiv\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-585f55e elementor-widget elementor-widget-text-editor\" data-id=\"585f55e\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<h3><span style=\"color: inherit;font-size: 2rem\">Fundamentals<\/span><\/h3>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-6daebec elementor-widget elementor-widget-text-editor\" data-id=\"6daebec\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<h4><b><span data-contrast=\"none\">Assessment<\/span><\/b><span data-ccp-props=\"{\"> <\/span><\/h4><p><span class=\"TextRun SCXW215400505 BCX4\" lang=\"DE-AT\" data-contrast=\"none\"><span class=\"NormalTextRun SCXW215400505 BCX4\">In the second quarter of 2026, Johnson &amp; Johnson once again reported strong business figures, confirming its position as one of the highest-quality healthcare companies worldwide. Growth was driven by both the <\/span><\/span><span class=\"TextRun SCXW215400505 BCX4\" lang=\"DE-AT\" data-contrast=\"none\"><span class=\"NormalTextRun SCXW215400505 BCX4\">Innovative Medicine<\/span><\/span><span class=\"TextRun SCXW215400505 BCX4\" lang=\"DE-AT\" data-contrast=\"none\"><span class=\"NormalTextRun SCXW215400505 BCX4\"> and <\/span><\/span><span class=\"TextRun SCXW215400505 BCX4\" lang=\"DE-AT\" data-contrast=\"none\"><span class=\"NormalTextRun SCXW215400505 BCX4\">MedTech<\/span><\/span><span class=\"TextRun SCXW215400505 BCX4\" lang=\"DE-AT\" data-contrast=\"none\"><span class=\"NormalTextRun SCXW215400505 BCX4\"> segments. Due to improved operational performance, management raised its full-year 2026 outlook despite ongoing competition from Stelara biosimilars.<\/span><\/span><span class=\"EOP Selected SCXW215400505 BCX4\" data-ccp-props=\"{}\"> <\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-bdf444c e-con e-atomic-element e-div-block-base image-container \" data-id=\"bdf444c\" data-element_type=\"e-div-block\" data-e-type=\"e-div-block\" data-interaction-id=\"bdf444c\" data-e-type=\"e-div-block\" data-id=\"bdf444c\">\n    \t\t<div class=\"elementor-element elementor-element-21f5cd2 elementor-widget elementor-widget-image\" data-id=\"21f5cd2\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/mumak.me\/wp-content\/uploads\/2026\/07\/JNJ_Finanzdaten-1-scaled.png\" data-elementor-open-lightbox=\"yes\" data-elementor-lightbox-title=\"JNJ Financial Data\" data-e-action-hash=\"#elementor-action%3Aaction%3Dlightbox%26settings%3DeyJpZCI6NjQ3MiwidXJsIjoiaHR0cHM6XC9cL211bWFrLm1lXC93cC1jb250ZW50XC91cGxvYWRzXC8yMDI2XC8wN1wvSk5KX0ZpbmFuemRhdGVuLTEtc2NhbGVkLnBuZyJ9\">\n\t\t\t\t\t\t\t<img fetchpriority=\"high\" decoding=\"async\" width=\"2560\" height=\"1072\" src=\"https:\/\/mumak.me\/wp-content\/uploads\/2026\/07\/JNJ_Finanzdaten-1-scaled.png\" class=\"attachment-full size-full wp-image-6472\" alt=\"JNJ Financial Data\" srcset=\"https:\/\/mumak.me\/wp-content\/uploads\/2026\/07\/JNJ_Finanzdaten-1-scaled.png 2560w, https:\/\/mumak.me\/wp-content\/uploads\/2026\/07\/JNJ_Finanzdaten-1-300x126.png 300w, https:\/\/mumak.me\/wp-content\/uploads\/2026\/07\/JNJ_Finanzdaten-1-1024x429.png 1024w, https:\/\/mumak.me\/wp-content\/uploads\/2026\/07\/JNJ_Finanzdaten-1-768x321.png 768w, https:\/\/mumak.me\/wp-content\/uploads\/2026\/07\/JNJ_Finanzdaten-1-1536x643.png 1536w, https:\/\/mumak.me\/wp-content\/uploads\/2026\/07\/JNJ_Finanzdaten-1-2048x857.png 2048w\" sizes=\"(max-width: 2560px) 100vw, 2560px\" \/>\t\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\n<\/div>\n\t\t<div class=\"elementor-element elementor-element-f49d960 elementor-widget elementor-widget-text-editor\" data-id=\"f49d960\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<h5><span class=\"TextRun SCXW21093991 BCX4\" lang=\"DE-AT\" data-contrast=\"none\"><span class=\"NormalTextRun SCXW21093991 BCX4\" data-ccp-parastyle=\"heading 3\">Financial Metrics<\/span><\/span><span class=\"EOP Selected SCXW21093991 BCX4\" data-ccp-props=\"{\"> <\/span><\/h5>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-c653961 elementor-widget elementor-widget-Table\" data-id=\"c653961\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"Table.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<table class=\"tafe-table \">\n\t\t\t<thead  class=\"tafe-table-header\">\n\t\t\t\t<tr>\n\t\t\t\t\t<th class=\"elementor-inline-editing elementor-repeater-item-3f3f2e0\"   >Key Figure<\/th><th class=\"elementor-inline-editing elementor-repeater-item-f44885d\"   >Q2 2026<\/th><th class=\"elementor-inline-editing elementor-repeater-item-c05f684\"   >Q2 2025<\/th><th class=\"elementor-inline-editing elementor-repeater-item-a237aa9\"   >Change<\/th>\t\t\t\t<\/tr>\n\t\t\t<\/thead>\n\t\t\t\t\t\t<tbody class=\"tafe-table-body\">\n\t\t\t\t<tr>\n\t\t\t\t\t<\/tr><tr><td data-label=\"Key Figure\"   class=\"elementor-repeater-item-e050aa7 td-content-type-default\" ><b>Revenue<\/b><\/td><td data-label=\"Q2 2026\"   class=\"elementor-repeater-item-da32a54 td-content-type-default\" >$25.31 bn \n<\/td><td data-label=\"Q2 2025\"   class=\"elementor-repeater-item-1efa44f td-content-type-default\" >$23.74 bn \n<\/td><td data-label=\"Change\"   class=\"elementor-repeater-item-f6f54c6 td-content-type-default\" ><b>+6,6 %<\/b>\n<\/td><\/tr><tr><td data-label=\"Key Figure\"   class=\"elementor-repeater-item-d27b099 td-content-type-default\" ><b>Net Profit<\/b><\/td><td data-label=\"Q2 2026\"   class=\"elementor-repeater-item-08a1df6 td-content-type-default\" >$5.53 bn \n<\/td><td data-label=\"Q2 2025\"   class=\"elementor-repeater-item-4d159be td-content-type-default\" >$5.54 bn \n<\/td><td data-label=\"Change\"   class=\"elementor-repeater-item-5d12ca9 td-content-type-default\" ><b>-0,1 %<\/b>\n<\/td><\/tr><tr><td data-label=\"Key Figure\"   class=\"elementor-repeater-item-e014835 td-content-type-default\" ><b>Diluted EPS<\/b><\/td><td data-label=\"Q2 2026\"   class=\"elementor-repeater-item-96a1917 td-content-type-default\" >$2.27\n<\/td><td data-label=\"Q2 2025\"   class=\"elementor-repeater-item-feded90 td-content-type-default\" >$2.29\n<\/td><td data-label=\"Change\"   class=\"elementor-repeater-item-46c5579 td-content-type-default\" ><b>-0,9 %<\/b>\n<\/td><\/tr><tr><td data-label=\"Key Figure\"   class=\"elementor-repeater-item-2c18166 td-content-type-default\" ><b>Adjusted net income <\/b><\/td><td data-label=\"Q2 2026\"   class=\"elementor-repeater-item-d036ffc td-content-type-default\" >$7.08 bn <\/td><td data-label=\"Q2 2025\"   class=\"elementor-repeater-item-5b58f5d td-content-type-default\" >$6.70 bn<\/td><td data-label=\"Change\"   class=\"elementor-repeater-item-ad18736 td-content-type-default\" ><b>+5,7 %  <\/b>\n<\/td><\/tr><tr><td data-label=\"Key Figure\"   class=\"elementor-repeater-item-3fdfc9d td-content-type-default\" ><b>Adjusted EPS <\/b><\/td><td data-label=\"Q2 2026\"   class=\"elementor-repeater-item-be2b700 td-content-type-default\" >$2.90<\/td><td data-label=\"Q2 2025\"   class=\"elementor-repeater-item-cf68888 td-content-type-default\" >$2.77 <\/td><td data-label=\"Change\"   class=\"elementor-repeater-item-1689295 td-content-type-default\" ><b>+4,7 %  <\/b>\n<\/td><\/tr><tr><td data-label=\"Key Figure\"   class=\"elementor-repeater-item-c6d0b65 td-content-type-default\" ><b>Free cash flow (YTD) <\/b><\/td><td data-label=\"Q2 2026\"   class=\"elementor-repeater-item-2d8d113 td-content-type-default\" >approx. $8.7 bn <\/td><td data-label=\"Q2 2025\"   class=\"elementor-repeater-item-259a66d td-content-type-default\" >$6.2 bn <\/td><td data-label=\"Change\"   class=\"elementor-repeater-item-f5141b2 td-content-type-default\" ><b>Significant improvement <\/b>\n<\/td>\t\t\t\t<\/tr>\n\t\t\t<\/tbody>\n\t\t<\/table>\n\t\t\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-01c6dbf elementor-widget elementor-widget-text-editor\" data-id=\"01c6dbf\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<h5><span class=\"TextRun SCXW169780287 BCX4\" lang=\"DE-AT\" data-contrast=\"none\"><span class=\"NormalTextRun SCXW169780287 BCX4\" data-ccp-parastyle=\"heading 4\">Revenue by business segment<\/span><\/span><span class=\"EOP Selected SCXW169780287 BCX4\" data-ccp-props=\"{\"> <\/span><\/h5>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-0b7d5cc elementor-widget elementor-widget-Table\" data-id=\"0b7d5cc\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"Table.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<table class=\"tafe-table \">\n\t\t\t<thead  class=\"tafe-table-header\">\n\t\t\t\t<tr>\n\t\t\t\t\t<th class=\"elementor-inline-editing elementor-repeater-item-3f3f2e0\"   >Segment <\/th><th class=\"elementor-inline-editing elementor-repeater-item-f44885d\"   >Revenue Q2 2026 <\/th><th class=\"elementor-inline-editing elementor-repeater-item-c05f684\"   >Reported<\/th><th class=\"elementor-inline-editing elementor-repeater-item-a237aa9\"   >Change<\/th>\t\t\t\t<\/tr>\n\t\t\t<\/thead>\n\t\t\t\t\t\t<tbody class=\"tafe-table-body\">\n\t\t\t\t<tr>\n\t\t\t\t\t<\/tr><tr><td data-label=\"Segment\"   class=\"elementor-repeater-item-e050aa7 td-content-type-default\" ><b>Innovative Medicine<\/b><\/td><td data-label=\"Revenue Q2 2026\"   class=\"elementor-repeater-item-da32a54 td-content-type-default\" >$16.38 bn <\/td><td data-label=\"Reported\"   class=\"elementor-repeater-item-1efa44f td-content-type-default\" >+7,8 % \n<\/td><td data-label=\"Change\"   class=\"elementor-repeater-item-f6f54c6 td-content-type-default\" ><b>+6,8 %<\/b>\n<\/td><\/tr><tr><td data-label=\"Segment\"   class=\"elementor-repeater-item-d27b099 td-content-type-default\" ><b>MedTech <\/b><\/td><td data-label=\"Revenue Q2 2026\"   class=\"elementor-repeater-item-08a1df6 td-content-type-default\" >$8.93 bn \n<\/td><td data-label=\"Reported\"   class=\"elementor-repeater-item-4d159be td-content-type-default\" >+4,5 %\n<\/td><td data-label=\"Change\"   class=\"elementor-repeater-item-5d12ca9 td-content-type-default\" ><b>+3,6 %  <\/b>\n<\/td>\t\t\t\t<\/tr>\n\t\t\t<\/tbody>\n\t\t<\/table>\n\t\t\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<a href=\"https:\/\/mumak.me\/wp-content\/uploads\/2026\/07\/JNJ_Voraussichtliche-Gewinn-und-Verlustrechnung-1.png\" target=\"_self\" class=\"e-image-link-base\" data-interaction-id=\"809039f\"\n\t><img decoding=\"async\" class=\"e-image-base \" data-e-type=\"widget\" data-id=\"809039f\" id=\"6564\" src=\"https:\/\/mumak.me\/wp-content\/uploads\/2026\/07\/JNJ_Voraussichtliche-Gewinn-und-Verlustrechnung-1.png\" width=\"1289\" height=\"984\" srcset=\"https:\/\/mumak.me\/wp-content\/uploads\/2026\/07\/JNJ_Voraussichtliche-Gewinn-und-Verlustrechnung-1.png 1289w, https:\/\/mumak.me\/wp-content\/uploads\/2026\/07\/JNJ_Voraussichtliche-Gewinn-und-Verlustrechnung-1-300x229.png 300w, https:\/\/mumak.me\/wp-content\/uploads\/2026\/07\/JNJ_Voraussichtliche-Gewinn-und-Verlustrechnung-1-1024x782.png 1024w, https:\/\/mumak.me\/wp-content\/uploads\/2026\/07\/JNJ_Voraussichtliche-Gewinn-und-Verlustrechnung-1-768x586.png 768w\" alt=\"JNJ_Projected income statement\"\/>\t<\/a>\t\t\t\t<div class=\"elementor-element elementor-element-f451985 elementor-widget elementor-widget-text-editor\" data-id=\"f451985\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<h5 class=\"PDq2pG_selectionAnchorContainer\" data-start=\"0\" data-end=\"35\"><strong data-start=\"0\" data-end=\"35\">Updated guidance for 2026<\/strong><\/h5><p class=\"PDq2pG_selectionAnchorContainer\" data-start=\"37\" data-end=\"136\">Johnson &amp; Johnson raised its full-year guidance following the strong second quarter.<\/p><p data-start=\"138\" data-end=\"228\" data-is-last-node=\"\" data-is-only-node=\"\">The company now expects reported sales of approximately <strong data-start=\"203\" data-end=\"227\">$100.8\u2013101.4 billion<\/strong>.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-d6b91cf elementor-widget elementor-widget-Table\" data-id=\"d6b91cf\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"Table.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<table class=\"tafe-table \">\n\t\t\t<thead  class=\"tafe-table-header\">\n\t\t\t\t<tr>\n\t\t\t\t\t<th class=\"elementor-inline-editing elementor-repeater-item-3f3f2e0\"   >Financial guidance <\/th><th class=\"elementor-inline-editing elementor-repeater-item-f44885d\"   >FY2024 <\/th><th class=\"elementor-inline-editing elementor-repeater-item-a237aa9\"   >FY2025<\/th><th class=\"elementor-inline-editing elementor-repeater-item-e51e8c5\"   >FY2026e<\/th>\t\t\t\t<\/tr>\n\t\t\t<\/thead>\n\t\t\t\t\t\t<tbody class=\"tafe-table-body\">\n\t\t\t\t<tr>\n\t\t\t\t\t<\/tr><tr><td data-label=\"Financial guidance\"   class=\"elementor-repeater-item-e050aa7 td-content-type-default\" ><b>Revenue <\/b><\/td><td data-label=\"FY2024\"   class=\"elementor-repeater-item-da32a54 td-content-type-default\" >$88.8 bn<\/td><td data-label=\"FY2025\"   class=\"elementor-repeater-item-f6f54c6 td-content-type-default\" >$94.2 billion\n<\/td><td data-label=\"FY2026e\"   class=\"elementor-repeater-item-7c2348f td-content-type-default\" >approx. $101 bn\n<\/td><\/tr><tr><td data-label=\"Financial guidance\"   class=\"elementor-repeater-item-d27b099 td-content-type-default\" ><b>Revenue Growth <\/b><\/td><td data-label=\"FY2024\"   class=\"elementor-repeater-item-08a1df6 td-content-type-default\" >approx. 4%\n<\/td><td data-label=\"FY2025\"   class=\"elementor-repeater-item-27f627d td-content-type-default\" >approx. 6%\n<\/td><td data-label=\"FY2026e\"   class=\"elementor-repeater-item-5d12ca9 td-content-type-default\" >approx. 7%\n<\/td><\/tr><tr><td data-label=\"Financial guidance\"   class=\"elementor-repeater-item-7d751a2 td-content-type-default\" ><b>EBITDA Margin <\/b><\/td><td data-label=\"FY2024\"   class=\"elementor-repeater-item-e24ffe6 td-content-type-default\" >approx. 35% <\/td><td data-label=\"FY2025\"   class=\"elementor-repeater-item-bf56166 td-content-type-default\" >approx. 36% <\/td><td data-label=\"FY2026e\"   class=\"elementor-repeater-item-47ff9fd td-content-type-default\" >approx. 37% \n<\/td><\/tr><tr><td data-label=\"Financial guidance\"   class=\"elementor-repeater-item-dc391e5 td-content-type-default\" ><b>Adjusted EPS <\/b><\/td><td data-label=\"FY2024\"   class=\"elementor-repeater-item-9b092f7 td-content-type-default\" >$9.98 <\/td><td data-label=\"FY2025\"   class=\"elementor-repeater-item-7ff24d8 td-content-type-default\" >$10.80<\/td><td data-label=\"FY2026e\"   class=\"elementor-repeater-item-b2c1bb8 td-content-type-default\" >$11.60\u2013$11.75 <\/td><\/tr><tr><td data-label=\"Financial guidance\"   class=\"elementor-repeater-item-67b9e5a td-content-type-default\" ><b>Free Cash Flow <\/b><\/td><td data-label=\"FY2024\"   class=\"elementor-repeater-item-8a2a436 td-content-type-default\" >$18.0 bn <\/td><td data-label=\"FY2025\"   class=\"elementor-repeater-item-a2d4464 td-content-type-default\" >$17.2 billion <\/td><td data-label=\"FY2026e\"   class=\"elementor-repeater-item-ce5a291 td-content-type-default\" >approx. $18\u2013$20 bn<\/td>\t\t\t\t<\/tr>\n\t\t\t<\/tbody>\n\t\t<\/table>\n\t\t\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-7013132 elementor-widget elementor-widget-text-editor\" data-id=\"7013132\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p class=\"PDq2pG_selectionAnchorContainer\" data-start=\"1178\" data-end=\"1224\"><em data-start=\"1178\" data-end=\"1224\">Source: MarketScreener.<\/em><\/p><h5 class=\"PDq2pG_selectionAnchorContainer\" data-start=\"0\" data-end=\"11\"><strong data-start=\"0\" data-end=\"11\">Opportunities<\/strong><\/h5><ul data-start=\"13\" data-end=\"589\"><li data-section-id=\"15g1mff\" data-start=\"13\" data-end=\"126\"><strong data-start=\"15\" data-end=\"27\">Darzalex<\/strong>, <strong data-start=\"29\" data-end=\"41\">Carvykti<\/strong>, <strong data-start=\"43\" data-end=\"54\">Tremfya<\/strong>, and <strong data-start=\"59\" data-end=\"71\">Spravato<\/strong> continue to support growth in the pharmaceutical business.<\/li><li data-section-id=\"eyw7ac\" data-start=\"127\" data-end=\"218\">The oncology pipeline offers several additional opportunities for future revenue growth.<\/li><li data-section-id=\"11qb8ge\" data-start=\"219\" data-end=\"309\">Improving free cash flow creates substantial financial flexibility.<\/li><li data-section-id=\"x5zkdj\" data-start=\"310\" data-end=\"454\">Strong cash flow generation supports investments in research and development, acquisitions, share buybacks, and dividend growth.<\/li><li data-section-id=\"1wuf1oa\" data-start=\"455\" data-end=\"589\">Johnson &amp; Johnson remains one of the most established companies with continuous dividend growth in the global healthcare sector.<\/li><\/ul><h5 data-start=\"591\" data-end=\"602\"><strong data-start=\"591\" data-end=\"602\">Risks<\/strong><\/h5><ul data-start=\"604\" data-end=\"1019\"><li data-section-id=\"1av8jg6\" data-start=\"604\" data-end=\"694\">Sales of <strong data-start=\"621\" data-end=\"632\">Stelara<\/strong> are increasingly under pressure from biosimilar competition.<\/li><li data-section-id=\"12z52hl\" data-start=\"695\" data-end=\"792\">New products must offset declining sales of established blockbuster drugs.<\/li><li data-section-id=\"v7xcma\" data-start=\"793\" data-end=\"901\">Acquisitions and investments in the product pipeline must deliver sufficient returns over the long term.<\/li><li data-section-id=\"1ut88xy\" data-start=\"902\" data-end=\"1019\">The comparatively high valuation increases sensitivity to weaker-than-expected earnings growth.<\/li><\/ul><p data-start=\"1021\" data-end=\"1046\"><strong data-start=\"1021\" data-end=\"1046\">Key takeaway: <\/strong>Johnson &amp; Johnson&#8217;s overall fundamental picture remains strong. Growth in Innovative Medicine and MedTech, improving free cash flow, and the raised 2026 guidance form a solid foundation. <\/p><p><span data-ccp-props=\"{}\"> <\/span><b><span data-contrast=\"none\">MUMAK.me Assessment Phase 3: Positive = 1 MUMAK<\/span><\/b><span data-ccp-props=\"{}\"> <\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-1834aeb elementor-widget elementor-widget-mumak_score_card\" data-id=\"1834aeb\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"mumak_score_card.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div class=\"mumak-score-card is-detail\" data-view=\"fundamentals\" style=\"--mumak-mammoth-mask: url(&quot;https:\/\/mumak.me\/wp-content\/uploads\/2026\/03\/Mammut-Clean-2.svg&quot;);\">\n\t\t\t\t\t\t\t\t\t<div class=\"mumak-score-card__detail\">\n\t\t\t<div class=\"mumak-score-card__detail-compass-wrap\">\n\t\t\t\t<img decoding=\"async\" class=\"mumak-score-card__detail-compass\" src=\"https:\/\/mumak.me\/wp-content\/uploads\/2026\/03\/Compass-Circle.svg\" alt=\"\" aria-hidden=\"true\">\n\t\t\t<\/div>\n\t\t\t<div class=\"mumak-score-card__detail-content\">\n\t\t\t\t<h4 class=\"mumak-score-card__company\">Johnson &amp; Johnson<\/h4>\n\t\t\t\t<div class=\"mumak-score-card__detail-mammoths\" aria-hidden=\"true\">\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"mumak-score-card__detail-mammoth is-inactive-positive\"><\/span>\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"mumak-score-card__detail-mammoth is-inactive-positive\"><\/span>\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"mumak-score-card__detail-mammoth is-active-positive\"><\/span>\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"mumak-score-card__detail-mammoth is-default\"><\/span>\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"mumak-score-card__detail-mammoth is-default\"><\/span>\n\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"mumak-score-card__detail-result\">\n\t\t\t\t\tRating Fundamentals: positiv\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-c15ab35 elementor-widget elementor-widget-text-editor\" data-id=\"c15ab35\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<h3>News, Analysts, and Market Sentiment<\/h3><h4>Assessment<\/h4><p class=\"PDq2pG_selectionAnchorContainer\" data-start=\"0\" data-end=\"111\">Market sentiment toward Johnson &amp; Johnson remains positive following the strong second-quarter results.<\/p><p data-start=\"113\" data-end=\"504\">Another important development concerns the long-standing litigation related to talc products. In July, Johnson &amp; Johnson announced a proposed comprehensive settlement intended to cover the remaining approximately <strong data-start=\"346\" data-end=\"416\">76,000 lawsuits related to ovarian cancer and talc products<\/strong>\u2014subject to sufficient participation and further conditions. <\/p><p data-start=\"506\" data-end=\"657\">Should this settlement be successfully concluded, it could significantly reduce one of the most persistent uncertainties surrounding the company.<\/p><p data-start=\"659\" data-end=\"959\" data-is-last-node=\"\" data-is-only-node=\"\">At the same time, the pharmaceutical pipeline continues to advance. The FDA granted <strong data-start=\"746\" data-end=\"766\">RYBREVANT FASPRO<\/strong> <strong data-start=\"784\" data-end=\"803\">Priority Review<\/strong> status for the treatment of recurrent or metastatic head and neck cancer, further strengthening Johnson &amp; Johnson&#8217;s position in oncology. <\/p><h5><span class=\"TextRun SCXW196063130 BCX4\" lang=\"DE-AT\" xml:lang=\"DE-AT\" data-contrast=\"none\"><span class=\"NormalTextRun SCXW196063130 BCX4\" data-ccp-parastyle=\"heading 3\">Analyst Consensus<\/span><\/span><span class=\"EOP SCXW196063130 BCX4\" data-ccp-props=\"{\"> <\/span><\/h5>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-3193062 elementor-widget elementor-widget-Table\" data-id=\"3193062\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"Table.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<table class=\"tafe-table \">\n\t\t\t<thead  class=\"tafe-table-header\">\n\t\t\t\t<tr>\n\t\t\t\t\t<th class=\"elementor-inline-editing elementor-repeater-item-3f3f2e0\"   ><\/th>\t\t\t\t<\/tr>\n\t\t\t<\/thead>\n\t\t\t\t\t\t<tbody class=\"tafe-table-body\">\n\t\t\t\t<tr>\n\t\t\t\t\t<\/tr><tr><td data-label=\"\"   class=\"elementor-repeater-item-e050aa7 td-content-type-default\" ><b>Average Consensus<\/b><\/td><td data-label=\"\"   class=\"elementor-repeater-item-35f1c12 td-content-type-default\" ><b>ACCUMULATE<\/b><\/td><\/tr><tr><td data-label=\"\"   class=\"elementor-repeater-item-abd253f td-content-type-default\" ><b>Number of Analysts <\/b><\/td><td data-label=\"\"   class=\"elementor-repeater-item-08a1df6 td-content-type-default\" >23\n<\/td><\/tr><tr><td data-label=\"\"   class=\"elementor-repeater-item-e9b18d8 td-content-type-default\" ><b>Average Price Target<\/b><\/td><td data-label=\"\"   class=\"elementor-repeater-item-19a0849 td-content-type-default\" >approx. $272<\/td><\/tr><tr><td data-label=\"\"   class=\"elementor-repeater-item-e52310b td-content-type-default\" ><b>Upside to the average target<\/b><\/td><td data-label=\"\"   class=\"elementor-repeater-item-ef05a60 td-content-type-default\" >approx. +4%\n<\/td><\/tr><tr><td data-label=\"\"   class=\"elementor-repeater-item-91165f8 td-content-type-default\" ><b>Highest price target<\/b><\/td><td data-label=\"\"   class=\"elementor-repeater-item-8833fb8 td-content-type-default\" >$305\n<\/td><\/tr><tr><td data-label=\"\"   class=\"elementor-repeater-item-85848b8 td-content-type-default\" ><b>Lowest Price Target<\/b><\/td><td data-label=\"\"   class=\"elementor-repeater-item-da32a54 td-content-type-default\" >USD 190  \n<\/td>\t\t\t\t<\/tr>\n\t\t\t<\/tbody>\n\t\t<\/table>\n\t\t\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-6d8310e elementor-widget elementor-widget-text-editor\" data-id=\"6d8310e\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p><i><span data-contrast=\"none\">Source: MarketScreener, as of August 2026.<\/span><\/i><span data-ccp-props=\"{\"> <\/span><\/p><p><span data-ccp-props=\"{}\"> <\/span><\/p><h5><b><span data-contrast=\"none\">Interesting Fact<\/span><\/b><span data-ccp-props=\"{\"> <\/span><\/h5><p><span class=\"TextRun SCXW14430230 BCX4\" lang=\"DE-AT\" data-contrast=\"none\"><span class=\"NormalTextRun SCXW14430230 BCX4\">Johnson &amp; Johnson is on track to <\/span><\/span><strong><span class=\"TextRun SCXW14430230 BCX4\" lang=\"DE-AT\" xml:lang=\"DE-AT\" data-contrast=\"none\"><span class=\"NormalTextRun SCXW14430230 BCX4\">achieve annual revenue exceeding $100 billion for the first time in its over 140-year corporate history<\/span><\/span><\/strong><span class=\"TextRun SCXW14430230 BCX4\" lang=\"DE-AT\" data-contrast=\"none\"><span class=\"NormalTextRun SCXW14430230 BCX4\">. This underscores the successful transformation of the company into a leading provider of innovative pharmaceuticals and modern medical technology.<\/span><\/span><span class=\"EOP Selected SCXW14430230 BCX4\" data-ccp-props=\"{}\"> <\/span><\/p><h5 class=\"PDq2pG_selectionAnchorContainer\" data-start=\"0\" data-end=\"11\"><strong data-start=\"0\" data-end=\"11\">Opportunities<\/strong><\/h5><ul data-start=\"13\" data-end=\"509\"><li data-section-id=\"8nrve7\" data-start=\"13\" data-end=\"96\">The raised 2026 guidance strengthens confidence in operational execution.<\/li><li data-section-id=\"ygbk82\" data-start=\"97\" data-end=\"276\">A potential resolution of the remaining litigation related to ovarian cancer and talc products could reduce a significant long-term uncertainty.<\/li><li data-section-id=\"1pkgqjt\" data-start=\"277\" data-end=\"417\">The FDA&#8217;s <strong data-start=\"304\" data-end=\"344\">Priority Review for RYBREVANT FASPRO<\/strong> underscores continued progress in the product pipeline.<\/li><li data-section-id=\"16q0ku6\" data-start=\"418\" data-end=\"509\">Strongly growing products are increasingly offsetting declining sales of <strong data-start=\"497\" data-end=\"508\">Stelara<\/strong>.<\/li><\/ul><h5 data-start=\"511\" data-end=\"522\"><strong data-start=\"511\" data-end=\"522\">Risks<\/strong><\/h5><ul data-start=\"524\" data-end=\"905\"><li data-section-id=\"9b0mkc\" data-start=\"524\" data-end=\"674\">The proposed talc litigation settlement remains subject to certain conditions and therefore does not immediately eliminate legal risk.<\/li><li data-section-id=\"1uqzydr\" data-start=\"675\" data-end=\"790\">Following the strong share price performance, the further upside potential expected by analysts is now more limited.<\/li><li data-section-id=\"9c44c5\" data-start=\"791\" data-end=\"905\">Disappointing clinical trial results or regulatory decisions could weigh on market sentiment.<\/li><\/ul><p data-start=\"907\" data-end=\"932\"><strong data-start=\"907\" data-end=\"932\">Key takeaway: <\/strong>Market sentiment remains positive, supported by strong business results and progress in the product pipeline.<\/p><h5><b style=\"font-size: 16px\"><span data-contrast=\"none\">MUMAK.me Evaluation Phase 4: Positive = 1 MUMAK<\/span><\/b><span style=\"font-size: 16px\" data-ccp-props=\"{}\"> <\/span><\/h5>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-85ec0d6 elementor-widget elementor-widget-mumak_score_card\" data-id=\"85ec0d6\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"mumak_score_card.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div class=\"mumak-score-card is-detail\" data-view=\"sentiment\" style=\"--mumak-mammoth-mask: url(&quot;https:\/\/mumak.me\/wp-content\/uploads\/2026\/03\/Mammut-Clean-2.svg&quot;);\">\n\t\t\t\t\t\t\t\t\t<div class=\"mumak-score-card__detail\">\n\t\t\t<div class=\"mumak-score-card__detail-compass-wrap\">\n\t\t\t\t<img decoding=\"async\" class=\"mumak-score-card__detail-compass\" src=\"https:\/\/mumak.me\/wp-content\/uploads\/2026\/03\/Compass-Circle.svg\" alt=\"\" aria-hidden=\"true\">\n\t\t\t<\/div>\n\t\t\t<div class=\"mumak-score-card__detail-content\">\n\t\t\t\t<h4 class=\"mumak-score-card__company\">Johnson &amp; Johnson<\/h4>\n\t\t\t\t<div class=\"mumak-score-card__detail-mammoths\" aria-hidden=\"true\">\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"mumak-score-card__detail-mammoth is-inactive-positive\"><\/span>\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"mumak-score-card__detail-mammoth is-inactive-positive\"><\/span>\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"mumak-score-card__detail-mammoth is-inactive-positive\"><\/span>\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"mumak-score-card__detail-mammoth is-active-positive\"><\/span>\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"mumak-score-card__detail-mammoth is-default\"><\/span>\n\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"mumak-score-card__detail-result\">\n\t\t\t\t\tRating Sentiment: positiv\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-1c81523 elementor-widget elementor-widget-text-editor\" data-id=\"1c81523\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<h3>Technical Analysis<\/h3><h4>Assessment<\/h4><p class=\"PDq2pG_selectionAnchorContainer\" data-start=\"0\" data-end=\"57\">The technical picture of Johnson &amp; Johnson remains positive.<\/p><p data-start=\"59\" data-end=\"365\">On August 18, 2026, the stock was trading at approximately <strong data-start=\"106\" data-end=\"120\">$268.54<\/strong>, slightly above the previous resistance level of around <strong data-start=\"185\" data-end=\"199\">$267.24<\/strong>. This is an important technical development, as a sustained rise above this level could confirm a continuation of the medium-term uptrend. <\/p><h5><span class=\"TextRun SCXW195081715 BCX4\" lang=\"DE-AT\" data-contrast=\"none\"><span class=\"NormalTextRun SCXW195081715 BCX4\" data-ccp-parastyle=\"heading 2\">Performance over recent weeks\/months<\/span><\/span><span class=\"EOP Selected SCXW195081715 BCX4\" data-ccp-props=\"{\"> (as of August 18, 2026)<\/span><\/h5>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-e0cb027 elementor-widget elementor-widget-Table\" data-id=\"e0cb027\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"Table.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<table class=\"tafe-table \">\n\t\t\t<thead  class=\"tafe-table-header\">\n\t\t\t\t<tr>\n\t\t\t\t\t<th class=\"elementor-inline-editing elementor-repeater-item-a4af3fd\"   >Indicator  <\/th><th class=\"elementor-inline-editing elementor-repeater-item-3b3ef9b\"   >Rating<\/th><th class=\"elementor-inline-editing elementor-repeater-item-21ece9f\"   >Interpretation<\/th>\t\t\t\t<\/tr>\n\t\t\t<\/thead>\n\t\t\t\t\t\t<tbody class=\"tafe-table-body\">\n\t\t\t\t<tr>\n\t\t\t\t\t<td data-label=\"Indicator\"   class=\"elementor-repeater-item-ca181a9 td-content-type-default\" ><b>RSI (14)<\/b><\/td><td data-label=\"Rating\"   class=\"elementor-repeater-item-24148b1 td-content-type-default\" ><b>Positive<\/b><\/td><td data-label=\"Interpretation\"   class=\"elementor-repeater-item-4b1ee9a td-content-type-default\" >At around 64.5; momentum is positive, while the stock is not yet in overbought territory.<\/td><\/tr><tr><td data-label=\"Indicator\"   class=\"elementor-repeater-item-750ef14 td-content-type-default\" ><b>MACD<\/b><\/td><td data-label=\"Rating\"   class=\"elementor-repeater-item-9d4c287 td-content-type-default\" ><b>Positive<\/b><\/td><td data-label=\"Interpretation\"   class=\"elementor-repeater-item-2f41ce7 td-content-type-default\" >The MACD remains slightly above the signal line, thereby supporting positive upward momentum.<\/td><\/tr><tr><td data-label=\"Indicator\"   class=\"elementor-repeater-item-da9ce5b td-content-type-default\" ><b>Bollinger Bands  <\/b><\/td><td data-label=\"Rating\"   class=\"elementor-repeater-item-5652068 td-content-type-default\" ><b>Positive<\/b><\/td><td data-label=\"Interpretation\"   class=\"elementor-repeater-item-186aaf5 td-content-type-default\" >The share price is above the middle band and moving toward the upper Bollinger Band.<\/td>\t\t\t\t<\/tr>\n\t\t\t<\/tbody>\n\t\t<\/table>\n\t\t\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-2de4740 elementor-widget elementor-widget-image\" data-id=\"2de4740\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/mumak.me\/wp-content\/uploads\/2026\/07\/JNJ-1-Tag-3.png\" data-elementor-open-lightbox=\"yes\" data-elementor-lightbox-title=\"JNJ 1 day\" data-e-action-hash=\"#elementor-action%3Aaction%3Dlightbox%26settings%3DeyJpZCI6ODM5NSwidXJsIjoiaHR0cHM6XC9cL211bWFrLm1lXC93cC1jb250ZW50XC91cGxvYWRzXC8yMDI2XC8wN1wvSk5KLTEtVGFnLTMucG5nIn0%3D\">\n\t\t\t\t\t\t\t<img decoding=\"async\" width=\"1869\" height=\"1077\" src=\"https:\/\/mumak.me\/wp-content\/uploads\/2026\/07\/JNJ-1-Tag-3.png\" class=\"attachment-full size-full wp-image-8395\" alt=\"JNJ 1 day\" srcset=\"https:\/\/mumak.me\/wp-content\/uploads\/2026\/07\/JNJ-1-Tag-3.png 1869w, https:\/\/mumak.me\/wp-content\/uploads\/2026\/07\/JNJ-1-Tag-3-300x173.png 300w, https:\/\/mumak.me\/wp-content\/uploads\/2026\/07\/JNJ-1-Tag-3-1024x590.png 1024w, https:\/\/mumak.me\/wp-content\/uploads\/2026\/07\/JNJ-1-Tag-3-768x443.png 768w, https:\/\/mumak.me\/wp-content\/uploads\/2026\/07\/JNJ-1-Tag-3-1536x885.png 1536w\" sizes=\"(max-width: 1869px) 100vw, 1869px\" \/>\t\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-8039a02 elementor-widget elementor-widget-text-editor\" data-id=\"8039a02\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<h5 class=\"PDq2pG_selectionAnchorContainer\" data-section-id=\"1hmotsa\" data-start=\"894\" data-end=\"910\"><span role=\"text\"><strong data-start=\"898\" data-end=\"910\">RSI (14)<\/strong><\/span><\/h5><p data-start=\"912\" data-end=\"923\"><strong data-start=\"912\" data-end=\"923\">Positive<\/strong><\/p><ul data-start=\"925\" data-end=\"1135\"><li data-section-id=\"dimo08\" data-start=\"925\" data-end=\"978\"><strong data-start=\"927\" data-end=\"949\">RSI at around 64.5:<\/strong> Momentum remains positive.<\/li><li data-section-id=\"d0zz27\" data-start=\"979\" data-end=\"1042\"><strong data-start=\"981\" data-end=\"993\">Above 50:<\/strong> Buying pressure is stronger than selling pressure.<\/li><li data-section-id=\"j6p0s9\" data-start=\"1043\" data-end=\"1135\"><strong data-start=\"1045\" data-end=\"1065\">Not overbought:<\/strong> The RSI remains below the usual overbought threshold of 70.<\/li><\/ul><p data-start=\"1137\" data-end=\"1155\"><strong data-start=\"1137\" data-end=\"1155\">Interpretation<\/strong><\/p><p data-start=\"1157\" data-end=\"1267\">The RSI signals positive momentum without current signs of an overbought market.<\/p><h5 data-section-id=\"1911kj6\" data-start=\"1269\" data-end=\"1291\"><span role=\"text\"><strong data-start=\"1273\" data-end=\"1291\">MACD (12\/26\/9)<\/strong><\/span><\/h5><p data-start=\"1293\" data-end=\"1304\"><strong data-start=\"1293\" data-end=\"1304\">Positive<\/strong><\/p><ul data-start=\"1306\" data-end=\"1552\"><li data-section-id=\"1p9gums\" data-start=\"1306\" data-end=\"1372\"><strong data-start=\"1308\" data-end=\"1327\">Positive MACD:<\/strong> The MACD remains above the zero line.<\/li><li data-section-id=\"u3ujb\" data-start=\"1373\" data-end=\"1446\"><strong data-start=\"1375\" data-end=\"1396\">Bullish signal:<\/strong> The MACD line is slightly above the signal line.<\/li><li data-section-id=\"uzzpu9\" data-start=\"1447\" data-end=\"1552\"><strong data-start=\"1449\" data-end=\"1475\">Improved momentum:<\/strong> The MACD indicates that upward momentum is strengthening again.<\/li><\/ul><p data-start=\"1554\" data-end=\"1572\"><strong data-start=\"1554\" data-end=\"1572\">Interpretation<\/strong><\/p><p data-start=\"1574\" data-end=\"1681\">The MACD supports the current uptrend, although the bullish signal remains moderate.<\/p><h5 data-section-id=\"1fnb8ax\" data-start=\"1683\" data-end=\"1712\"><span role=\"text\"><strong data-start=\"1687\" data-end=\"1712\">Bollinger Bands (20)<\/strong><\/span><\/h5><p data-start=\"1714\" data-end=\"1725\"><strong data-start=\"1714\" data-end=\"1725\">Positive<\/strong><\/p><ul data-start=\"1727\" data-end=\"1995\"><li data-section-id=\"to4i7\" data-start=\"1727\" data-end=\"1807\"><strong data-start=\"1729\" data-end=\"1748\">Middle band:<\/strong> The middle Bollinger Band is at approximately <strong data-start=\"1792\" data-end=\"1806\">$260.38<\/strong>.<\/li><li data-section-id=\"17qp6ld\" data-start=\"1808\" data-end=\"1884\"><strong data-start=\"1810\" data-end=\"1827\">Lower band:<\/strong> The lower Bollinger Band is at approximately <strong data-start=\"1869\" data-end=\"1883\">$252.26<\/strong>.<\/li><li data-section-id=\"171zoup\" data-start=\"1885\" data-end=\"1995\"><strong data-start=\"1887\" data-end=\"1917\">Resistance at $267.24:<\/strong> The share price has moved slightly above this important resistance level.<\/li><\/ul><p data-start=\"1997\" data-end=\"2015\"><strong data-start=\"1997\" data-end=\"2015\">Interpretation<\/strong><\/p><p data-start=\"2017\" data-end=\"2197\">The Bollinger Bands confirm the positive overall technical picture. The share price is trading above the middle band and moving in the upper range of the Bollinger bandwidth. <\/p><h5 data-section-id=\"jcz0dm\" data-start=\"2199\" data-end=\"2214\"><span role=\"text\"><strong data-start=\"2203\" data-end=\"2214\">Opportunities<\/strong><\/span><\/h5><ul data-start=\"2216\" data-end=\"2520\"><li data-section-id=\"17cjd8\" data-start=\"2216\" data-end=\"2333\"><strong data-start=\"2218\" data-end=\"2241\">Positive momentum:<\/strong> The share price has recovered significantly and remains in an uptrend.<\/li><li data-section-id=\"1ljnvwm\" data-start=\"2334\" data-end=\"2424\"><strong data-start=\"2336\" data-end=\"2353\">Healthy RSI:<\/strong> The RSI is above 50 but remains below overbought territory.<\/li><li data-section-id=\"gj7w73\" data-start=\"2425\" data-end=\"2520\"><strong data-start=\"2427\" data-end=\"2446\">Positive MACD:<\/strong> The indicator supports a possible continuation of the upward movement.<\/li><\/ul><h5 data-section-id=\"3w2smf\" data-start=\"2522\" data-end=\"2537\"><span role=\"text\"><strong data-start=\"2526\" data-end=\"2537\">Risks<\/strong><\/span><\/h5><ul data-start=\"2539\" data-end=\"2898\"><li data-section-id=\"176s5m9\" data-start=\"2539\" data-end=\"2655\"><strong data-start=\"2541\" data-end=\"2575\">Breakout not yet confirmed:<\/strong> The share price must hold sustainably above the recent resistance level.<\/li><li data-section-id=\"1u5rhwf\" data-start=\"2656\" data-end=\"2773\"><strong data-start=\"2658\" data-end=\"2680\">Relatively high RSI:<\/strong> Momentum is strong; however, the risk of a short-term correction is rising.<\/li><li data-section-id=\"1ds3c6j\" data-start=\"2774\" data-end=\"2898\"><strong data-start=\"2776\" data-end=\"2803\">Weakening momentum:<\/strong> A decline below the middle Bollinger Band would weaken the positive technical picture.<\/li><\/ul><p data-section-id=\"1raylle\" data-start=\"2900\" data-end=\"2929\"><span role=\"text\"><strong data-start=\"2904\" data-end=\"2929\">Key takeaway: <\/strong><\/span>The technical picture of Johnson &amp; Johnson remains positive. The stock has moved slightly above the important resistance level of <strong data-start=\"3055\" data-end=\"3069\">$267.24<\/strong>, supported by positive RSI and MACD signals. A sustained breakout above this level would further confirm the uptrend.  <\/p><p><b><span data-contrast=\"none\">MUMAK.me Assessment Phase 5: Positive = 1 MUMAK<\/span><\/b><span data-ccp-props=\"{}\"> <\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-c14d35e elementor-widget elementor-widget-mumak_score_card\" data-id=\"c14d35e\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"mumak_score_card.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div class=\"mumak-score-card is-detail\" data-view=\"sentiment\" style=\"--mumak-mammoth-mask: url(&quot;https:\/\/mumak.me\/wp-content\/uploads\/2026\/03\/Mammut-Clean-2.svg&quot;);\">\n\t\t\t\t\t\t\t\t\t<div class=\"mumak-score-card__detail\">\n\t\t\t<div class=\"mumak-score-card__detail-compass-wrap\">\n\t\t\t\t<img decoding=\"async\" class=\"mumak-score-card__detail-compass\" src=\"https:\/\/mumak.me\/wp-content\/uploads\/2026\/03\/Compass-Circle.svg\" alt=\"\" aria-hidden=\"true\">\n\t\t\t<\/div>\n\t\t\t<div class=\"mumak-score-card__detail-content\">\n\t\t\t\t<h4 class=\"mumak-score-card__company\">Johnson &amp; Johnson<\/h4>\n\t\t\t\t<div class=\"mumak-score-card__detail-mammoths\" aria-hidden=\"true\">\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"mumak-score-card__detail-mammoth is-inactive-positive\"><\/span>\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"mumak-score-card__detail-mammoth is-inactive-positive\"><\/span>\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"mumak-score-card__detail-mammoth is-inactive-positive\"><\/span>\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"mumak-score-card__detail-mammoth is-active-positive\"><\/span>\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"mumak-score-card__detail-mammoth is-default\"><\/span>\n\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"mumak-score-card__detail-result\">\n\t\t\t\t\tRating Sentiment: positiv\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-2528c0e elementor-widget elementor-widget-text-editor\" data-id=\"2528c0e\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<h5><span data-contrast=\"none\">What speaks for Johnson &amp; Johnson?<\/span><span data-ccp-props=\"{\"> <\/span><\/h5><ul><li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"37\" data-list-defn-props=\"{\" data-aria-posinset=\"1\" data-aria-level=\"1\"><b><span data-contrast=\"none\">Raised 2026 full-year guidance<\/span><\/b><span data-contrast=\"none\"> after a strong second quarter.<\/span><span data-ccp-props=\"{\"> <\/span><\/li><\/ul><ul><li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"37\" data-list-defn-props=\"{\" data-aria-posinset=\"2\" data-aria-level=\"1\"><b><span data-contrast=\"none\">Diversified business model<\/span><\/b><span data-contrast=\"none\"> with Innovative Medicine and MedTech segments.<\/span><span data-ccp-props=\"{\"> <\/span><\/li><\/ul><ul><li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"37\" data-list-defn-props=\"{\" data-aria-posinset=\"3\" data-aria-level=\"1\"><b><span data-contrast=\"none\">Globally leading oncology portfolio<\/span><\/b><span data-contrast=\"none\"> with Darzalex and Carvykti as growth drivers.<\/span><span data-ccp-props=\"{\"> <\/span><\/li><\/ul><ul><li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"37\" data-list-defn-props=\"{\" data-aria-posinset=\"4\" data-aria-level=\"1\"><b><span data-contrast=\"none\">Very strong balance sheet<\/span><\/b><span data-contrast=\"none\"> and excellent free cash flow generation.<\/span><span data-ccp-props=\"{\"> <\/span><\/li><\/ul><ul><li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"37\" data-list-defn-props=\"{\" data-aria-posinset=\"5\" data-aria-level=\"1\"><b><span data-contrast=\"none\">Dividend Aristocrat<\/span><\/b><span data-contrast=\"none\"> with more than <\/span><b><span data-contrast=\"none\">60<\/span><\/b><span data-contrast=\"none\"> consecutive dividend increases.<\/span><span data-ccp-props=\"{\"> <\/span><\/li><\/ul><ul><li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"37\" data-list-defn-props=\"{\" data-aria-posinset=\"6\" data-aria-level=\"1\"><b><span data-contrast=\"none\">Broad late-stage pipeline<\/span><\/b><span data-contrast=\"none\"> and targeted acquisitions like <\/span><b><span data-contrast=\"none\">Firefly Bio<\/span><\/b><span data-contrast=\"none\"> strengthen long-term growth.<\/span><span data-ccp-props=\"{\"> <\/span><\/li><\/ul><p><span data-ccp-props=\"{\"> <\/span><\/p><h5><span data-contrast=\"none\">What speaks against Johnson &amp; Johnson?<\/span><span data-ccp-props=\"{\"> <\/span><\/h5><ul><li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"37\" data-list-defn-props=\"{\" data-aria-posinset=\"7\" data-aria-level=\"1\"><span data-contrast=\"none\">Ongoing revenue decline for <\/span><b><span data-contrast=\"none\">Stelara<\/span><\/b><span data-contrast=\"none\"> due to biosimilar competition.<\/span><span data-ccp-props=\"{\"> <\/span><\/li><\/ul><ul><li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"37\" data-list-defn-props=\"{\" data-aria-posinset=\"8\" data-aria-level=\"1\"><span data-contrast=\"none\">Increasing price and reimbursement pressure in key healthcare markets.<\/span><span data-ccp-props=\"{\"> <\/span><\/li><\/ul><ul><li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"37\" data-list-defn-props=\"{\" data-aria-posinset=\"9\" data-aria-level=\"1\"><span data-contrast=\"none\">The ongoing <\/span><b><span data-contrast=\"none\">talc lawsuits<\/span><\/b><span data-contrast=\"none\"> remain a factor of uncertainty despite improved transparency.<\/span><span data-ccp-props=\"{\"> <\/span><\/li><\/ul><ul><li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"37\" data-list-defn-props=\"{\" data-aria-posinset=\"10\" data-aria-level=\"1\"><span data-contrast=\"none\">Regulatory and clinical risks in the development of new products.<\/span><span data-ccp-props=\"{\"> <\/span><\/li><\/ul><ul><li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"37\" data-list-defn-props=\"{\" data-aria-posinset=\"11\" data-aria-level=\"1\"><span data-contrast=\"none\">The <\/span><b><span data-contrast=\"none\">premium valuation<\/span><\/b><span data-contrast=\"none\"> leaves only limited room for operational disappointments.<\/span><span data-ccp-props=\"{\"> <\/span><\/li><\/ul><h5> <\/h5><h5><span data-contrast=\"none\">What we are watching<\/span><span data-ccp-props=\"{\"> <\/span><\/h5><ul><li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"37\" data-list-defn-props=\"{\" data-aria-posinset=\"12\" data-aria-level=\"1\"><span data-contrast=\"none\">Implementation of the <\/span><b><span data-contrast=\"none\">raised 2026 full-year guidance<\/span><\/b><span data-contrast=\"none\">.<\/span><span data-ccp-props=\"{\"> <\/span><\/li><\/ul><ul><li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"37\" data-list-defn-props=\"{\" data-aria-posinset=\"13\" data-aria-level=\"1\"><span data-contrast=\"none\">Further growth of <\/span><b><span data-contrast=\"none\">Darzalex, Carvykti, Tremfya, Spravato, Tecvayli<\/span><\/b><span data-contrast=\"none\"> and <\/span><b><span data-contrast=\"none\">Talvey<\/span><\/b><span data-contrast=\"none\">.<\/span><span data-ccp-props=\"{\"> <\/span><\/li><\/ul><ul><li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"37\" data-list-defn-props=\"{\" data-aria-posinset=\"14\" data-aria-level=\"1\"><span data-contrast=\"none\">Successful replacement of declining <\/span><b><span data-contrast=\"none\">Stelara<\/span><\/b><span data-contrast=\"none\"> revenues with new products.<\/span><span data-ccp-props=\"{\"> <\/span><\/li><\/ul><ul><li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"37\" data-list-defn-props=\"{\" data-aria-posinset=\"15\" data-aria-level=\"1\"><span data-contrast=\"none\">Integration of <\/span><b><span data-contrast=\"none\">Firefly Bio<\/span><\/b><span data-contrast=\"none\"> and progress of the oncology pipeline.<\/span><span data-ccp-props=\"{\"> <\/span><\/li><\/ul><ul><li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"37\" data-list-defn-props=\"{\" data-aria-posinset=\"16\" data-aria-level=\"1\"><span data-contrast=\"none\">Further approvals of new drugs and product launches in the MedTech sector in the second half of <\/span><b><span data-contrast=\"none\">2026<\/span><\/b><span data-contrast=\"none\">.<\/span><span data-ccp-props=\"{\"> <\/span><\/li><\/ul>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-afade06 elementor-widget elementor-widget-text-editor\" data-id=\"afade06\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<h2>Summary<\/h2><p class=\"PDq2pG_selectionAnchorContainer\" data-start=\"0\" data-end=\"324\">Johnson &amp; Johnson continues to confirm its strong position within the <strong data-start=\"74\" data-end=\"96\">UMBRELLA strategy<\/strong>. The strong second-quarter results, the raised 2026 guidance, and the sustained growth in key areas of Innovative Medicine and MedTech underscore the strength of the underlying business. <\/p><p class=\"\" data-start=\"326\" data-end=\"734\">Progress in the pharmaceutical product pipeline supports future growth, while the proposed settlement of the remaining lawsuits related to ovarian cancer and talc products could significantly reduce a long-standing uncertainty. At the same time, the technical picture also remains positive, with the share price having surpassed an important resistance level. <\/p><p data-start=\"736\" data-end=\"979\" data-is-last-node=\"\" data-is-only-node=\"\">Overall, the <strong data-start=\"758\" data-end=\"904\">diversified business model, the leading oncology portfolio, strong cash flow generation, and the broadly positioned product pipeline<\/strong> continue to support our positive long-term assessment of Johnson &amp; Johnson.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-2a3f9ae elementor-widget elementor-widget-text-editor\" data-id=\"2a3f9ae\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<h3>Rating According to the MUMAK Method<\/h3>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-73448fb elementor-widget elementor-widget-Table\" data-id=\"73448fb\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"Table.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<table class=\"tafe-table \">\n\t\t\t<thead  class=\"tafe-table-header\">\n\t\t\t\t<tr>\n\t\t\t\t\t<th class=\"elementor-inline-editing elementor-repeater-item-a4af3fd\"   >Category<\/th><th class=\"elementor-inline-editing elementor-repeater-item-3b3ef9b\"   >Rating<\/th>\t\t\t\t<\/tr>\n\t\t\t<\/thead>\n\t\t\t\t\t\t<tbody class=\"tafe-table-body\">\n\t\t\t\t<tr>\n\t\t\t\t\t<td data-label=\"Category\"   class=\"elementor-repeater-item-ca181a9 td-content-type-default\" ><b>Geopolitics<\/b><\/td><td data-label=\"Rating\"   class=\"elementor-repeater-item-24148b1 td-content-type-default\" >Positive<\/td><\/tr><tr><td data-label=\"Category\"   class=\"elementor-repeater-item-750ef14 td-content-type-default\" ><b>Industry<\/b><\/td><td data-label=\"Rating\"   class=\"elementor-repeater-item-b92892f td-content-type-default\" >Positive<\/td><\/tr><tr><td data-label=\"Category\"   class=\"elementor-repeater-item-da9ce5b td-content-type-default\" ><b>Fundamentals<\/b><\/td><td data-label=\"Rating\"   class=\"elementor-repeater-item-9492819 td-content-type-default\" >Positive<\/td><\/tr><tr><td data-label=\"Category\"   class=\"elementor-repeater-item-6f870ed td-content-type-default\" ><b>News &amp; Sentiment<\/b><\/td><td data-label=\"Rating\"   class=\"elementor-repeater-item-1c7f62f td-content-type-default\" >Positive<\/td><\/tr><tr><td data-label=\"Category\"   class=\"elementor-repeater-item-ca1b684 td-content-type-default\" ><b>Technical Analysis<\/b><\/td><td data-label=\"Rating\"   class=\"elementor-repeater-item-5f69e06 td-content-type-default\" >Positive<\/td>\t\t\t\t<\/tr>\n\t\t\t<\/tbody>\n\t\t<\/table>\n\t\t\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-11acf94 elementor-widget elementor-widget-text-editor\" data-id=\"11acf94\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<h3>Overall Rating<\/h3>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-5dc067f elementor-widget elementor-widget-mumak_score_card\" data-id=\"5dc067f\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"mumak_score_card.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div class=\"mumak-score-card is-detail\" data-view=\"overall\" style=\"--mumak-mammoth-mask: url(&quot;https:\/\/mumak.me\/wp-content\/uploads\/2026\/03\/Mammut-Clean-2.svg&quot;);\">\n\t\t\t\t\t\t\t\t\t<div class=\"mumak-score-card__detail mumak-score-card__detail--overall\">\n\t\t\t<div class=\"mumak-score-card__detail-compass-wrap\">\n\t\t\t\t<img decoding=\"async\" class=\"mumak-score-card__detail-compass\" src=\"https:\/\/mumak.me\/wp-content\/uploads\/2026\/03\/Compass-Circle.svg\" alt=\"\" aria-hidden=\"true\">\n\t\t\t<\/div>\n\t\t\t<div class=\"mumak-score-card__detail-content\">\n\t\t\t\t<h4 class=\"mumak-score-card__company\">Johnson &amp; Johnson<\/h4>\n\t\t\t\t<div class=\"mumak-score-card__detail-mammoths\" aria-hidden=\"true\">\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"mumak-score-card__detail-mammoth is-active-positive\"><\/span>\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"mumak-score-card__detail-mammoth is-active-positive\"><\/span>\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"mumak-score-card__detail-mammoth is-active-positive\"><\/span>\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"mumak-score-card__detail-mammoth is-active-positive\"><\/span>\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"mumak-score-card__detail-mammoth is-active-positive\"><\/span>\n\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"mumak-score-card__detail-result\">\n\t\t\t\t\tAnalysis result: 5 out of 5 MUMAKS\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>Johnson &#038; Johnson is one of the world&#8217;s leading healthcare companies. The company benefits from a strong position in pharmaceuticals and medical technology, a robust innovation pipeline, and an exceptionally solid balance sheet.  <\/p>\n","protected":false},"author":5,"featured_media":2318,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[183,171],"tags":[311,380,378,375,377,329],"aktie":[372],"class_list":["post-4079","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-valuation-analysis","category-active","tag-dividend-stocks","tag-healthcare-sector","tag-jnj","tag-johnson-johnson","tag-medical-technology","tag-pharmaceutical-industry","aktie-johnson-johnson"],"acf":[],"_links":{"self":[{"href":"https:\/\/mumak.me\/en\/wp-json\/wp\/v2\/posts\/4079","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mumak.me\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mumak.me\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mumak.me\/en\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/mumak.me\/en\/wp-json\/wp\/v2\/comments?post=4079"}],"version-history":[{"count":34,"href":"https:\/\/mumak.me\/en\/wp-json\/wp\/v2\/posts\/4079\/revisions"}],"predecessor-version":[{"id":8400,"href":"https:\/\/mumak.me\/en\/wp-json\/wp\/v2\/posts\/4079\/revisions\/8400"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/mumak.me\/en\/wp-json\/wp\/v2\/media\/2318"}],"wp:attachment":[{"href":"https:\/\/mumak.me\/en\/wp-json\/wp\/v2\/media?parent=4079"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mumak.me\/en\/wp-json\/wp\/v2\/categories?post=4079"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mumak.me\/en\/wp-json\/wp\/v2\/tags?post=4079"},{"taxonomy":"aktie","embeddable":true,"href":"https:\/\/mumak.me\/en\/wp-json\/wp\/v2\/aktie?post=4079"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}